Fortress Biotech, Inc.
FBIOP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001429260
No open-market purchases or sales by Fortress Biotech, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesFBIO
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding FBIOP, Q2 2026
No superinvestor reported holding FBIOP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Fortress Biotech, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2024 (view filing)4:45 PM ET | Sep 23 | 2 days | Rosenwald Lindsay A MDPRESIDENT, CEO & CHAIRMAN | PPurchaseCommon stock, par value $0.001 | +763.4K | $1.84 | +$1.40M | +26.4%3.66M after | |
| Sep 25, 2024 (view filing)4:45 PM ET | Sep 23 | 2 days | Rosenwald Lindsay A MDPRESIDENT, CEO & CHAIRMAN | PPurchase | +763.4K | $0.125 | +$95.4K | –763.4K after | Derivative |
| Jul 15, 2024 (view filing) | Jul 11 | 4 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +5.00K | $7.48 | +$37.4K | +4.1%127.5K after | |
| Jul 12, 2024 (view filing) | Jul 10 | 2 days | Jin DavidChief Financial Officer | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +500 | $7.50 | +$3.75K | New position500 after | |
| Jul 11, 2024 (view filing) | Jul 9 | 2 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +5.00K | $7.39 | +$37.0K | +4.3%122.5K after | |
| Jul 10, 2024 (view filing) | Jul 8 | 2 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +5.00K | $7.35 | +$36.8K | +4.4%117.5K after | |
| Jul 1, 2024 (view filing) | Jun 28 | 3 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseCOMMON STOCK, PAR VALUE $0.001 | +20.0K | $1.64 | +$32.8K | +0.7%2.89M after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseCOMMON STOCK, PAR VALUE $0.001 | +10.0K | $1.76 | +$17.6K | +0.3%2.87M after | |
| May 20, 2024 (view filing) | May 20 | Same day | Klein DovDirector | SSaleCOMMON STOCK, PAR VALUE $0.001 | −10.0K | $1.89 | −$18.9K | −15.8%53.4K after | |
| Jan 9, 2024 (view filing) | Jan 5 | 4 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseCOMMON STOCK, PAR VALUE $0.001 | +50.0K | $2.38 | +$119.0K | +1.8%2.86M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Fortress Biotech, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding FBIOP in 13F filings for Q2 2026.